In oncology, the patient state is characterized by a whole spectrum of modalities, ranging
from radiology, histology, and genomics to electronic health records. Current artificial …

Integrins are cell adhesion and signalling proteins crucial to a wide range of biological
functions. Effective marketed treatments have successfully targeted integrins αIIbβ3 …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few
treatment options. Here, building on the observation of elevated lactate (LA) in resected …

Glioblastoma (GBM) is an aggressive brain cancer with an immunosuppressive tumor
microenvironment. Here, a copper-based nanoplatform BSO-CAT@ MOF-199@ DDM …

In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Background Nowadays, conventional medical treatments such as surgery, radiotherapy, and
chemotherapy cannot cure all types of cancer. A promising approach to treat solid tumors is …

Glioblastoma multiforme (GBM) is one of the most fatal malignancies due to the existence of
blood-brain barrier (BBB) and the difficulty to maintain an effective drug accumulation in …

Glioblastoma (GBM) is highly invasive and the deadliest brain tumor in adults. It is
characterized by inter-tumor and intra-tumor heterogeneity, short patient survival, and lack of …